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=Abstract=To examine whether there are  abnormalities in growth hormone 
(GH) response to  clonidine among treatment-resistant schizophrenics, the authors 
investigated the GH response t o  clonidine in 20 treatment-resistant male 
schizophrenics and in 16 normal controls. There was no statistically significant 
difference in the mean maximal AGH, the level of GH at any observed time point, 
the mean duration required for the peak of GH response and the percentage of 
the blunted GH response between the treatment-resistant schizophrenics regard- 
less of haloperidol administration and normal controls except for much wider 
variations of maximal AGH values in the treatment-resistant schizophrenics. In 
the relationship between the clinical variables and GH responsiveness, under the 
haloperidol medication no clinical variables were related with maximal AGH, but 
2 weeks after discontinuation of haloperidol, withdrawal-retardation subscore of 
BPRS was negatively correlated with maximal AGH. Similarly, in a comparison 
between the GH responsive and the blunted group, only at  haloperidol withdrawal 
state, did the blunted group show a higher withdrawal-retardation subscore of 
BPRS. 
Key W o rd s : Treatment-resistant schizophrenia, Growth hormone. Clunidine, Blurzte~1' response, 
Withdr-nbcal- rerardution 
INTRODUCTION 
It is well known that about 10-30% of 
schizophrenics show poor or no response to 
neuroleptic treatment and are categorized as 
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treatment-resistant schizophrenia (Kane et a/.  
1988). This group may be a homogenous sub- 
group at a certain dimension of pathophysiology. 
And there have beer? some reports that treat- 
ment-resistant schizophrenics have some abnor- 
malities in their nor-adrenergic (NA) systems 
(Bowers 1990). Therefore, it is worthwhile to 
examine whether there are abnormalities of GH 
response to clonidine, an 0,-adrenergic agonist, 
In treatment-resistant schizophrenia. If there are 
some abnormalities in GH response to clonidine, 
these may be served as a neuroendocrine mark- 
er for treatment-resistance. 
According to the results of previous studies, 
in schizophrenics as a whole, the GH responses 
to clonidine showed great variations. For exam- 
p le ,  increased GH responses in paranoid 
schizophrenics (Matussek et a/. 1980) and blunt- 
ed GH responses among the schizophrenics 
who had negative symptoms (Miiller-Spahn et a/. 
1986) and who had been treated with neurolep- 
tics for more than 5 years (Ackenheil et a/. 1985) 
were reported. On the other hand, Lal et a/ .  
(1983) and our previous results (Shin eta/ .  1989) 
showed that there was no difference in GH 
response between chronic schizophrenics and 
the normal controls. 
Clonidine stimulates GH secretion via 
growth hormone releasing factor (GHRH) by 
stimulating hypothalamic a,-adrenergic postsy- 
naptic receptors (Lal 1987). Recently, it has 
been reported that there is no difference 
between normal controls and schizophrenics 
regarding GH secretion via GHRH. And this sug- 
gests that i f  there is any abnormality in GH 
secretion in schizophrenics it derives from 
suprapituitary dysfunction (Mayerhoff et a/. 1990; 
Liberman and Koreen 1993). The secretion of 
GH is also regulated by dopaminergic, choliner- 
gic, GABAergic, and serotonergic neurotransmit- 
ter systems along with many other variables that 
may involve hypothalamic pathways (Pearsall 
and Gold 1986; Lal 1987; Liberman and Koreen 
1993). So it is a very important issue in the study 
of GH response to clonidine, to restrict these 
confounding variables including the effects of 
antipsychotics on the a,-adrenergic receptors. 
We observed the GH response to clonidine 
in a relatively homogenous cohort of treatment- 
resistant schizophrenics, i.e., we included only 
male subjects whose age, age of onset and 
weight ratio were within a narrow range, and we 
have restricted current antipsychotic medica- 
tions to only haloperidol which has relatively low 
affinities for the a,-adrenergic and the choliner- 
gic receptors in comparison with the other popu- 
lar antipsychotics (Richelson and Nelson 1984; 
Blak and Richelson 1987), and we also moni- 
tored the effects of haloperidol on dopaminergic 
(DA) neurons by measuring the level of plasma 
prolactin (Pearsall and Gold 1986). 
SUBJECTS AND METHODS 
Subjects 
The subjects were 21 male schizophrenics 
who were admitted to Yong-In Mental Hospital 
ranging from 20 to 46 years in age. They were 
diagnosed with the diagnostic criteria of DSM-III- 
R (American Psychiatric Association 1990) and 
met the following criteria for the treatment-resis- 
tance adopted by Keefe et a/. (1987) with some 
modifications. The criteria are the presence of 
persistent psychopathology showing some signs 
of personality deterioration and requiring admis- 
sion for more than 5 years despite that the 
patients had been treated for at least 5 years 
with two different chemical classes of antipsy- 
chotics amounting to more than 1000mg of 
chlorpromazine (CPZ) equivalent. 
None of the subjects had any history of 
head trauma, neurological diseases, endocrine 
disorders, and any abnormalities in routine labo- 
ratory examinations inc luding electroen- 
cephalography. Consents were obtained from all 
subjects after an explanation of the purpose and 
process of this study had been given. The mean 
age of the subjects was 33.9 + 5.3 years and 
the mean weight ratio (ideal weightlcurrent 
weight) of the subjects was 1.00 + 0.12. The 
mean age of onset and the mean duration of the 
illness were 21.9 + 4.8 years and 12.0 + 4.3 
years, respectively. 
Normal controls were 19 healthy males who 
did not have any history of endocrine, neurologi- 
cal and psychiatric disorders within their second 
degree of relatives. They were also informed of 
the procedures of this study and gave their con- 
sent. The mean age of the normal controls was 
32.7 + 6.4 years and the mean weight ratio of 
them was 1.1 f 0.18. 
We started giving all patients only haloperi- 
do1 as antipsychotics two weeks before the chal- 
lenge of clonidine. The dosage of haloperidol 
was the equivalent of the antipsychotics that the 
patients had been receiving previously. No medi- 
cation that affects GH response was allowed 
throughout the experiment. 
Methods 
Clonidine challenges were done twice. The 
first challenge was done two weeks after we 
changed all previously administered antipsy- 
chotics to haloperidol. Immediately after the first 
challenge, we withdrew haloperidol. The second 
challenge was done after haloperidol had been 
withdrawn for two weeks. 
As clinical variables, we obtained the infor- 
mation on the age of onset, the duration of ill- 
ness, the highest dose of antipsychotics during 
the hospitalization and the dosage of antipsy- 
chotics at the beginning of this study. The 
dosages of antipsychotics were converted to the 
CPZ equivalent dose (Baldessarini 1985). 
For the evaluation of the psychopathology, 
the Brief Psychiatric Rating Scale (BPRS, Overall 
1976) was applied. The BPRS scores were sub- 
grouped as paranoid, thought, withdrawal-retar- 
dation and anxiety-depression clusters. The rat- 
ings were done the day before clonidine chal- 
lenge. 
All the patients and controls had fasted from 
10 p.m. on the night before the test and had 
been restricted to lie in bed during the whole 
procedures. For the clonidine challenge, an 
intravenous indwelling catheter was inserted at 
7:30 a.m. After one hour of stabilization, blood 
was drawn for the baseline and then 0.15mg of 
clonidine was introduced for 10 minutes. Blood 
samples were collected at 15, 30, 45, 60 and 
120 minutes after the start of the infusion of 
clonidine. Blood pressure was also taken at the 
time of collecting blood samples. Plasma was 
separated and kept at -70" C until analysis. The 
plasma levels of GH anG prolactin were mea- 
sured with a radioimmunoassay (RIA) kit 
(Diagnostic Products Corporation; Sensitivity = 
0.9 nglml). 
Data analysis 
Before the analysis of data, we excluded 
one subject frorn the schizophrenics and three 
from the normal controls because their baseline 
levels of GH were above 5ngIml (Murad and 
Hynes 1985). Finally, the data from 20 
schizophrenics and 16 normal controls were 
analyzed. The levels of GH were measured as 
two ways, AGH (the level of GH after the cloni- 
dine challenge minus the baseline level of GH) 
and AUC (area under the curve), the sum of the 
trapezoid areas. However, because these two 
values showed significant correlation (r = 0.90, p 
< 0.01 and r = 0.98, p < 0.01, on and off-drug 
respectively), we analyzed only the AGH of the 
result. The subjects were divided into the AGH 
responsive and the blunted groups according to 
maximal AGH. The responsive group included 
those who showed 5nglml or more in maximal 
AGH, and the blunted group included those 
whose maximal AGH were less than 5nglml 
according to Hunt et a1.(1986). As statistical 
methods, multivariate analysis of variables 
(ANOVA), multivariate analysis of covariance 
(ANCOVA), Student's t-test, Pearson's product 
movement correlation coefficient, kappa value 
and $-test were used. All the statistical analyses 
were conducted using the Statistical Package for 
the Social Sciences for Personal Computer 
(SPSSIPC +). A P value of 0.05 was taken to be 
statistically significant. 
RESULTS 
GH response after clonidine challenge in 
treatment-resistant schizophrenics and normal 
controls 
There was no statistically significant differ- 
ence in maximal AGH between the treatment- 
resistant schizophrenics with (10.02 t 10. 
82nglml) or without (8.07 -+ 7.89nglml) haloperi- 
do1 administration and normal controls (8.32 i 
4.67nglml) except for significantly wider varia- 
tions of maximal AGH values in the treatment- 
resistant schizophrenics (F = 5.36, p < 0.05 and 
F = 2.85, p<0.05 normal control vs. on and off- 
haloperidol, respectively, Fig. 1). Also no signifi- 
cant difference was observed in the levels of GH 
between treatment-resistant schizophrenics 
regardless of haloperidol administration and nor- 
mal controls at any time point from the baseline 
to 2 hours after the clonidine challenge (Fig. 2). 
And the mean durations required for the peak of 
GH response were again not significantly differ- 
ent between the treatment-resistant schizophren- 
ics with (40.6 + 10.3 min) or without (43.1 + 16. 
3 min) haloperidol administration and normal 
controls (42.0 + 16.2 min, Fig.2). 
There was no statistically significant differ- 
ence regarding the percentage of blunted GH 
response between schizophrenics with or without 
haloperidol administration and normal controls 
(Table 1) .  Of the 7 schizophrenics who showed 
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Fig.1. Maximal growth hormone increment (AGH, 
nglml) in response to clonidine challenge (0. 
15mg i.v.).Each dot represents each subject. The 
interrupted lines and squares represent mean 
and SD respectively. 
blunted GH response under haloperidol, 5 
patients (71.4%) showed blunted response with- 
out haloperidol. And of the 13 schizophrenics who 
were included in the responsive group under the 
medication, 8 patients (61.5%) maintained 
responsiveness in haloperidol withdrawn state. 
However, there was no statistically significant con- 
cordance in GH responsiveness between the on 
and off haloperidol state (Kappa = 0.15). 
Clinical variables and the GH response to cloni- 
dine challenge 
Under the haloperidol medication, there was 
no statistically significant correlation between the 
maximal AGH and any clinical variables, i.e., 
age, age of onset, duration of illness, dosage of 
haloperidol at the day of challenge, maximal 
dosage of neuroleptics, baseline serum level of 
prolact in,  total and subscores of BPRS 
(paranoid, thought, withdrawal-retardation and 
anxiety- depression clusters). When we divided 
the patients into the GH responsive and the 
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Fig.2. Time course of plasma growth hormone 
concentration after infusion of clonidine (0. 
15mg i.v.) in treatment-resistant schizoph- 
renics on and off haloperidol medication (n 
= 20) and in normal controls (n = 16). 
"SPR: schizophrenics. 
No significant differences between the 
schizophrenics regardless of haloperidol 
medication and normal controls. 
Table 1 Comparison of GH response between treatment-resistant schizophrenics on and off haloperidol and nor- 
mal controls. 
.- pp - - - - - - -- - .- - - - 
Treatment resistant schizophrenics 
-  - - - - - -- -. -- -  .-  Normal Controls 
On-haloperidol Off-haloperidol (n = 16) 
(n = 20) (n = 20) 
-- - - - ~ - 
Responsive group 13(65'/0) 10(50%) 12(75%) 
Blunted group* 7(35%) 10(50%) 4(25%) 
- -- 
*Blunted group: maximal GH Increment after clonidine injection < 5nglml 
~2 = 0.41 d.f .=  1 p = 0.522 > 0.05, statistically not significant (on - off) 
X* = 0.08 d.f. = 1 p = 0.777 > 0.05; stat~st~cally not significant (on - control) 
~2 = 1.40 d.f. = 1 p = 0.236 > 0.05; stat~stically not significant (off - control) 
blunted groups during medication, comparison 
between the two showed no statistically signifi- 
cant difference in the clinical variables men- 
tioned above (Table 2). 
However, after 2 weeks of haloperidol with- 
drawal, age was posltlvely correlated with maxi- 
mal AGH response (r = 0.44, p < 0.05), and with- 
drawal-retardation subscore of BPRS was nega- 
tively correlated with maximal AGH (r = - 0.44, p 
< 0.05). In comparison between the responsive 
and the blunted group, the blunted group 
showed significar~tly younger aye (36.2 f 5.4 
years and 31.6 t 4.1 years, the responsive and 
the blunted group, respectively), significantly 
higher total score (48.9 -t- 9.5 vs. 58.7 2 10.1) 
and withdrawal-retardation subscore (8.7 F 0.7 
vs. 11.4 f 2.9) of BPRS at p < 0.05 (Table 2). 
However, according to ANCOVA with the age 
factor as covariate, the total scores of BPRS 
were not significantly different between the 
blunted and responsive groups (F value of main 
effects = 2.872, p = 0.108) but the withdrawal- 
retardation subscore of BPRS was still signifi- 
cantly higher in the blunted group (F value of 
main effects = 5.243, p = 0.035). 
DISCUSSION 
We investigated whether there are abnor- 
malities in GH response to clonldine among 
treatment-resistant schizophren~cs. Because a 
lot of variables influence the secretion of GH, we 
tried to construct a homogenous cohort with 
strict control of several variables, for example, 
sex of subject, range of age, age of onset and 
weight ratio, and we also adopted operational 
criteria for the treatment-resistance. Furthermore, 
during the experiment we restricted the antipsy- 
chotic medication to only haloperidol and moni- 
tored the extent of haloperidol induced DA 
antagonism by measuring the level of plasma 
prolactin. 
From this we found that GH response to 
clonidine chal lenge in treatment-resistant 
schizophrenics is not different from normal con- 
trols regardless of haloperidol administration and 
that haloperidol medication does not affect the 
GH response in schizophrenics. Ttiese findings 
are consistent with the report of Lal (1983) and 
our previous observation (Shin et a/ .  1989), 
which showed no difference between chronic 
schizophrenics and normal control in the GH 
response to clonidine. These findings are also 
consistent with the report of Ackenheil et a/. 
(1985), who argued that in chronic schizophren- 
ics 5 and 10 days of neuroleptic-withdrawal do 
not affect the GH secretion response to clonidine 
stimulation. Therefore, it could be assumed that 
the treatment-resistant schizophrenics as a 
group may not differ from normal controls in u2- 
adrenergic responsiveness regardless of the 
dopaminergic antagonism. Nevertheless, there 
are some reservations in concluding that the 
treatment-resistant schizophrenics do not have 
Table 2. Clinical characterist~cs of the GH responsive group and blunted group on and off haloperidol medication 
in treatment-resistant schizophrenics 
Age 
Age of onset 









- -. . 
Responsive G Blunted G Responsive G Blunted G 
(n = 13) (n = 7) (n = 10) (n = lo )  
-- -~ - - .- - 
33.2 t 6.0 35.1 t 3.6 36.2 + 5.4 31.6 i 4.1* 
24.1 i 5.1 22.7 t 4.5 23.7 2 3.3 20.4 i 5.3 
11.8 f 5.2 12.3 i 1.6 '2.5 i 4.2 11.1 + 4.3  
* p < 0.05 
Responsive G; responsive group, Blunted G; blunted group, P-cluster; paranoid cluster, T-cluster; thought cluster, 
WR-cluster; withdrawal-retardation cluster, AD-cluster; anxiety-depression cluster 
any alterations in a2-adrenergic responsiveness. 
Because our present experiment, strictly con- 
trolled in a relative sense, showed wider varia- 
tions of maximal AGH values regardless of 
haloperidol medication, which is consistent with 
previous reports (Ackenheil et a/. 1985: Shin et 
a/. 1 989). 
In addition we observed that after the with- 
drawal of haloperidol, withdrawal-retardation 
subscore of BPRS was negatively correlated with 
maximal AGH, whereas there is no correlation 
between the clinical variables and the GH 
responsiveness under haloperidol medication. 
Similarly, although there was no significant differ- 
ence in any clinical variable between the respon- 
sive and blunted groups under the haloperidol 
medication, in haloperidol withdrawal state, the 
blunted GH responsive group showed higher 
withdrawal-retardation subscore of BPRS. These 
findings are partly compatible with Muller-Spahn 
et a1.(1986), who reported reduced GH response 
to clonidine in negative schizophrenics after 12 
days of drug withdrawal but no difference 
between schizophrenics and normal controls 
during medication. 
It is interesting but difficult to interpret why 
the withdrawal of haloper~dol induces correlation 
between the degree of GH change and psy- 
chopathology, even though the mean maximal 
AGH, the total score and other subscores of 
BPRS were not different between on and off 
states of haloperidol. A possible explanation 
may be  that during the administration of 
haloperidol, various drug related variables might 
have blurring effects on the relationship between 
the clinical variables and the GH response, and 
after 2-weeks withdrawal of the medication, 
these blurring effects were removed. However, 
our previous study done with chronic but not all 
of them treatment-resistant schizophrenics (Shin 
et a/. 1989) showed no correlation between clini- 
cal variables and the GH response after with- 
drawal of medication. So in drug withdrawal 
state, it is possible to assume that GH response 
to clonidine could be related with negative 
symptoms of not all but some schizophrenics. Of 
course, other interpretations are possible. One of 
them is that this might be an accidental finding 
because small number of the samples has low 
statistical power and our sc~~izophrenics showed 
wider variations of maximal AGH values and no 
concordance in terms of bluntedness between 
on and off-drug state. So in further studies, clari- 
fying the GH response to clonidine in various 
subgroups with a large number of patients at dif- 
ferent dimensions of pathophysiology and psy- 
chopathology, and systematic evaluation of the 
effects of chronic antipsychotic medication and 
its withdrawal on the GH response may be need- 
ed. 
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